Clinical Trials Logo

Clinical Trial Details — Status: Suspended

Administrative data

NCT number NCT04589065
Other study ID # HUM00178335
Secondary ID
Status Suspended
Phase N/A
First received
Last updated
Start date September 2024
Est. completion date December 2025

Study information

Verified date October 2023
Source University of Michigan
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this clinical trial is to see if a new device (SCD) is safe and if it can reduce damage to the kidney enough to allow medications to work to improve heart and kidney function for use in patients that have moderate to severe heart failure and is at least in part due to heart failure and it not responding to standard medical therapy. The SCD is a cartridge used with a commercial hemodialysis unit. Participants will be enrolled in the clinical trial once eligibility is confirmed. In addition to clinical assessments and laboratory testing participants will have surface echocardiograms during the trial. The SCD treatment will take place for 4 hours on day 1, 3, and 5 while on hemodialysis.


Recruitment information / eligibility

Status Suspended
Enrollment 10
Est. completion date December 2025
Est. primary completion date December 2025
Accepts healthy volunteers No
Gender All
Age group 21 Years to 70 Years
Eligibility Inclusion Criteria: - Primary hospitalization for acute decompensated chronic systolic heart failure as defined: - Left ventricular ejection fraction =35% as confirmed by baseline imaging procedure. - New York Heart Association (NYHA) class III or IV chronic (= 90 days) systolic heart failure, with failure to respond to optimal medical therapy (beta blocker, Angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blockers (ARB) or valsartan/sacubitril, aldosterone antagonist, unless not tolerated or contraindicated, and loop diuretic, as needed) for 45 of the last 60 days. - Baseline Estimated Glomerular Filtration Rate (eGFR)** = 40 ml/min/1.73 m2 (baseline defined as the highest known eGFR within 90 days of study enrollment) - Worsening renal failure (WRF), defined for the purposes of this study as increase serum creatinine = 0.5 mg/dL from baseline (baseline defined as the lowest known serum creatinine within 90 days of study enrollment) - Cardiorenal syndrome is the most likely explanation for WRF - Persistent signs and /or symptoms of congestion (peripheral edema, dyspnea, pulmonary rales, neck vein distension) despite optimal medical therapy including intravenous diuretic therapy and an estimated need for greater than 5 kg. of fluid removal. For the purposes of this study, optimal intravenous diuretic therapy is defined as: - Furosemide equivalent total daily dose of 240 mg (furosemide 40mg=1mg bumetanide) - Furosemide equivalent dose given either as a single or multiple intravenous bolus or continuous infusion - A furosemide equivalent total daily dose <240 mg if the dose has resulted in >3000 ml urine output/24 hours Exclusion Criteria: - Prior sensitivity to dialysis device components - Individual with known hypersensitivity to citrate - Bacteremia or possible infection, as evidence by fever, white blood cell count > 10,000/microliter, or any other signs of acute or chronic infection, and any patient receiving antibiotic or antiviral therapy. - Active malignancy requiring chemotherapy, biological therapy or radiation therapy. - The use of intravenous iodinated contrast agent within the prior 72 hours or the anticipated use of such an agent during SCD therapy. - Need for intravenous vasopressor (i.e., phenylephrine, vasopressin), intravenous. vasoconstricting inotrope (i.e., norepinephrine or epinephrine) or dopamine > 3 mcg/kg/min. (Note: use of vasodilating inotropes [i.e., dobutamine and milrinone] or dopamine at = 3 mcg/kg/min will not preclude study inclusion). - Persistent systolic blood pressure (SBP) < 80 mmHg. - White blood cell (WBC)<4000/microliter. - Platelets < 50,000/microliter. - Serum creatinine > 4 mg/dL or receiving dialysis / continuous renal replacement therapy (CRRT) - Acute coronary syndrome within the past month. - Women who are pregnant, breastfeeding a child, or trying to become pregnant. - Subject not able to sign informed consent. - Use of any other investigational drug or device within the previous 30 days - Concurrent enrollment in another interventional clinical trial. Patients enrolled in clinical studies where only measurements and/or samples are taken (i.e., no test device or test drug used) are allowed to participate.

Study Design


Intervention

Device:
Selective Cytopheretic Device
SCD therapy will take place for 4 hours on day 1, 3, and 5 while on hemodialysis treatment. Participants will be continue to be followed until 30 days after the last SCD treatment.

Locations

Country Name City State
United States University of Michigan Ann Arbor Michigan

Sponsors (1)

Lead Sponsor Collaborator
Lenar Yessayan

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Improvement in Cardiac Function - Left Ventricular Ejection Fraction This will be assessed by surface echocardiography. up to 4 weeks following last SCD treatment
Secondary Improved renal function as measured by serum creatinine up to 4 weeks following the last SCD therapy
Secondary Improved renal function as measured by blood urea nitrogen (BUN) up to 4 weeks following the last SCD therapy
See also
  Status Clinical Trial Phase
Recruiting NCT05654272 - Development of CIRC Technologies
Recruiting NCT05196659 - Collaborative Quality Improvement (C-QIP) Study N/A
Recruiting NCT05650307 - CV Imaging of Metabolic Interventions
Active, not recruiting NCT05896904 - Clinical Comparison of Patients With Transthyretin Cardiac Amyloidosis and Patients With Heart Failure With Reduced Ejection Fraction N/A
Completed NCT05077293 - Building Electronic Tools To Enhance and Reinforce Cardiovascular Recommendations - Heart Failure
Recruiting NCT05631275 - The Role of Bioimpedance Analysis in Patients With Chronic Heart Failure and Systolic Ventricular Dysfunction
Enrolling by invitation NCT05564572 - Randomized Implementation of Routine Patient-Reported Health Status Assessment Among Heart Failure Patients in Stanford Cardiology N/A
Enrolling by invitation NCT05009706 - Self-care in Older Frail Persons With Heart Failure Intervention N/A
Recruiting NCT04177199 - What is the Workload Burden Associated With Using the Triage HF+ Care Pathway?
Terminated NCT03615469 - Building Strength Through Rehabilitation for Heart Failure Patients (BISTRO-STUDY) N/A
Recruiting NCT06340048 - Epicardial Injection of hiPSC-CMs to Treat Severe Chronic Ischemic Heart Failure Phase 1/Phase 2
Recruiting NCT05679713 - Next-generation, Integrative, and Personalized Risk Assessment to Prevent Recurrent Heart Failure Events: the ORACLE Study
Completed NCT04254328 - The Effectiveness of Nintendo Wii Fit and Inspiratory Muscle Training in Older Patients With Heart Failure N/A
Completed NCT03549169 - Decision Making for the Management the Symptoms in Adults of Heart Failure N/A
Recruiting NCT05572814 - Transform: Teaching, Technology, and Teams N/A
Enrolling by invitation NCT05538611 - Effect Evaluation of Chain Quality Control Management on Patients With Heart Failure
Recruiting NCT04262830 - Cancer Therapy Effects on the Heart
Completed NCT06026683 - Conduction System Stimulation to Avoid Left Ventricle Dysfunction N/A
Withdrawn NCT03091998 - Subcu Administration of CD-NP in Heart Failure Patients With Left Ventricular Assist Device Support Phase 1
Recruiting NCT05564689 - Absolute Coronary Flow in Patients With Heart Failure With Reduced Ejection Fraction and Left Bundle Branch Block With Cardiac Resynchronization Therapy